MRNA cancer therapy takes on tough B-Cell tumors
NCT ID NCT07332663
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new mRNA drug called WGb-0301 in 9 patients with B-cell cancers (like lymphoma or leukemia) that have come back or stopped responding to treatment. The drug uses lipid nanoparticles to deliver mRNA that targets a protein called CD19 on cancer cells. The main goal is to check safety and find the right dose, not yet to cure the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- WGb-0301 injection (mRNA therapy targeting CD19, delivered via lipid nanoparticles)
- What this could lead to
- If it works, this could point toward a new treatment option for patients with B-cell cancers that have stopped responding to standard therapies.
- What could go wrong
- This is a very early, small trial (9 people) focused on safety, not effectiveness. The treatment may not work or could have unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Double-Targeted immune cells take aim at Hard-to-Treat blood cancers
- Double-Pronged immune cells take aim at blood cancers
- Double-Pronged CAR-T cells take aim at Hard-to-Treat blood cancers
- Off-the-Shelf CAR t cells take on tough blood cancers
- Hidden danger: why some patients can't shake COVID-19
- New drug HRS-1635 enters early human testing for hard-to-treat blood cancers